Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases

Neurology

Volumn 56, Issue 1, 2001, Pages 94-96

  Chaudhry, V ^a,b   Cornblath, D R ^a   Griffin, J W ^a   O'Brien, R ^a   Drachman, D B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PURINE SYNTHESIS; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 0035830428     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.1.94     Document Type: Article

References (10)

1. Myasthenia gravis: Immunological mechanisms and immunotherapy
2. Idiopathic inflammatory myopathies
3. Treatment of immune-mediated inflammatory neuropathies
4. Mechanisms of action of mycophenolic acid
5. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection
6. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease
7. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial
8. Therapy of rheumatoid arthritis with mycophenolate mofetil
9. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis
10. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil